Children’s Hospital of Philadelphia (CHOP) has been recognized by the 2023 Disability Equality Index (DEI) as a leader in “Best Places to Work for Disability Inclusion.”

The Neurologic Infections Clinic at Children’s Hospital of Philadelphia (CHOP) was established to enhance clinical care for children with definite or suspected, acute and chronic, standard and emerging infections of the central nervous system. We combine pediatric neurology and pediatric infectious diseases expertise to optimize multidisciplinary evaluation, acute care and long-term management of these children. 

Agenesis of the corpus callosum (ACC) is one of the most common referrals seen in the prenatal period at the Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment (CFDT) at Children’s Hospital of Philadelphia (CHOP). 

Christopher Cielo, DO, joined the Division of Pulmonary and Sleep Medicine at Children’s Hospital of Philadelphia (CHOP) in 2010 and is an attending pulmonologist.

CHOP researchers suggest more targeted intervention against discrimination, particularly in states with higher rates of structural stigma.

Dr. Lori Handy talks about pneumococcal infections in kids, the complications that can result in hospitalization, and why pneumococcal vaccines were more difficult to make than some other vaccine-preventable bacterial infections.

Watch "Marion Gruber: Preparedness Is Prevention," a film that showcases Dr. Gruber’s years working as a scientist at the FDA.

Find info about pneumococcal vaccine, the disease it prevents, and recent updates that have led to revised vaccine recommendations.

CHOP and Penn researchers have developed a proof-of-concept model for delivering gene editing tools to treat blood disorders directly within the body.

Children’s Hospital of Philadelphia (CHOP) announced it has received $1 million from Pediatric Cancer Foundation, an organization that has been raising funds for research since 1970 to support doctors and hospitals in an effort to eradicate childhood cancer. The grant will help to fund a planned first-in-human phase 1 clinical trial led by Sarah K. Tasian, MD, which will use a new immunotherapy to target the FLT3 receptor protein in high-risk pediatric leukemias.